PolyPeptide Group AG (SWX:PPGN)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
15.86
-0.20 (-1.25%)
Apr 4, 2025, 10:39 AM CET

PolyPeptide Group AG Company Description

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India.

It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies.

The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices.

PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

PolyPeptide Group AG
Country Switzerland
Founded 1952
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,362
CEO Juan Gonzalez

Contact Details

Address:
Neuhofstrasse 24
Baar, 6340
Switzerland
Phone 41 435 020 580
Website polypeptide.com

Stock Details

Ticker Symbol PPGN
Exchange SIX Swiss Exchange
Fiscal Year January - December
Reporting Currency EUR
ISIN Number CH1110760852
SIC Code 8731

Key Executives

Name Position
Juan Jose Gonzalez Chief Executive Officer
Marc Augustin Chief Financial Officer
Jens Fricke Director of Global Operations
Rene Vestergaard Director of Corporate Finance
Olivier Ludemann-Hombourger Director of Global Innovation and Technology
Michael Staheli Head of Investor Relations and Corporate Communications
Christina Del Vecchio Chief Legal Officer and Corporate Secretary
Andreas Liese Corporate Compliance Manager
Trishul Shah MS Interim Director Global Sales and Marketing
Monika Casanova Chief Human Resources Officer